Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.40 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17186528 | 0.99 | ADORA3 (0.50) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| SCHEMBL6268523 | 0.97 | ADORA2B (0.53) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| Hydrochloric Acid SCHEMBL17186427 | 0.96 | ADORA2B (0.52) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| SCHEMBL17186483 | 0.93 | ADORA3 (0.46) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| Hydrochloric Acid SCHEMBL17186273 | 0.92 | ADORA3 (0.46) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| SCHEMBL17186230 | 0.90 | ADORA3 (0.53) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| SCHEMBL17186529 | 0.90 | ADORA3 (0.44) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| Hydrochloric Acid SCHEMBL17186399 | 0.89 | ADORA3 (0.52) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| Hydrochloric Acid SCHEMBL17186458 | 0.89 | ADORA3 (0.43) | ADORA3ADORA2BKMT2AMEN1KDM4E | |
| SCHEMBL17186294 | 0.88 | ADORA3 (0.40) | ADORA3ADORA2BKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | claimed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | claimed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | ADORA3 1244/4885ADORA2B 1776/4885KMT2A 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.